Biota Technology, the pioneer of industrial genomics, today announces the creation of a new business line to manage pathogen risk in the post-pandemic economy.
Following the recent transaction with Novozymes, Biota is launching diagnostics in an emerging, high-growth opportunity to further broaden its genomic platform: high throughput genomic monitoring of wastewater to detect and defend against pathogen risks.
Biota recently entered into a collaboration with Pangolin Health to develop technical workflows and analytic methods for a number of customers in the Southwestern US. “Biota offered us the opportunity to leverage their extraordinary work in difficult industrial environments into the similarly challenging wastewater setting. Because pathogen detection in wastewater is comprehensive, inclusive and always on, it’s an instrumental source of critical data for pandemic management and control. This is relevant both for the current coronavirus and its variant strains, and the next pathogen,” says, Dr. Bryan Walser.
Sustainable growth for the global energy market Along with new investments in pathogen diagnostics, Biota continues to grow its core energy business.
“With a global footprint in the energy market and rapidly growing market for pathogen risk management, Biota has the corporate strategy, commercial scale, and technical capabilities to develop new solutions across the industrial sector and create a billion-dollar enterprise.”